Bone turnover markers: basic biology to clinical applications
M Schini, T Vilaca, F Gossiel, S Salam… - Endocrine …, 2023 - academic.oup.com
Bone turnover markers (BTMs) are used widely, in both research and clinical practice. In the
last 20 years, much experience has been gained in measurement and interpretation of these …
last 20 years, much experience has been gained in measurement and interpretation of these …
[HTML][HTML] The clinician's guide to prevention and treatment of osteoporosis
MS LeBoff, SL Greenspan, KL Insogna… - Osteoporosis …, 2022 - Springer
Osteoporosis is the most common metabolic bone disease in the USA and the world. It is a
subclinical condition until complicated by fracture (s). These fractures place an enormous …
subclinical condition until complicated by fracture (s). These fractures place an enormous …
[HTML][HTML] IL-6/JAK/STAT3 signaling in breast cancer metastasis: biology and treatment
SG Manore, DL Doheny, GL Wong, HW Lo - Frontiers in oncology, 2022 - frontiersin.org
Breast cancer is the most commonly diagnosed cancer in women. Metastasis is the primary
cause of mortality for breast cancer patients. Multiple mechanisms underlie breast cancer …
cause of mortality for breast cancer patients. Multiple mechanisms underlie breast cancer …
Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis …
C Ayers, D Kansagara, B Lazur, R Fu… - Annals of internal …, 2023 - acpjournals.org
An update is available for this article. Background: The prevalence of osteoporosis is
increasing in the United States. Purpose: To evaluate low bone mass and osteoporosis …
increasing in the United States. Purpose: To evaluate low bone mass and osteoporosis …
The 2022 hormone therapy position statement of the North American Menopause Society
SS Faubion, CJ Crandall, L Davis… - …, 2022 - ingentaconnect.com
“The 2022 Hormone Therapy Position Statement of The North American Menopause
Society”(NAMS) updates “The 2017 Hormone Therapy Position Statement of The North …
Society”(NAMS) updates “The 2017 Hormone Therapy Position Statement of The North …
Update on osteoporosis screening and management
AK Anam, K Insogna - Medical Clinics, 2021 - medical.theclinics.com
Osteoporosis is a metabolic bone disease characterized by low bone mass and
microarchitectural deterioration of the bone tissue, leading to reduced bone strength and …
microarchitectural deterioration of the bone tissue, leading to reduced bone strength and …
Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline
Objective The objective is to formulate clinical practice guidelines for the pharmacological
management of osteoporosis in postmenopausal women. Conclusions Evidence from …
management of osteoporosis in postmenopausal women. Conclusions Evidence from …
[HTML][HTML] Osteoporosis: Pathophysiology and therapeutic options
U Föger-Samwald, P Dovjak, U Azizi-Semrad… - EXCLI …, 2020 - ncbi.nlm.nih.gov
Osteoporosis is a metabolic bone disease that, on a cellular level, results from osteoclastic
bone resorption not compensated by osteoblastic bone formation. This causes bones to …
bone resorption not compensated by osteoblastic bone formation. This causes bones to …
Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update
Objective The objective is to provide an update of the 2019 Pharmacological Management
of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice …
of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice …